NGF-induced mechanical sensitization of the masseter muscle is mediated through peripheral NMDA receptors
Introduction
Nerve growth factor (NGF) is a neurotrophin essential for the growth and survival of sympathetic and small diameter sensory afferent fibers (Bennett, 2001, Pezet and MacMahon, 2006). It may also play a role in chronic muscle pain development (Stohler, 1997). Recent clinical trials found anti-NGF antibodies to be efficacious in treating osteoarthritic pain and chronic low back pain (Lane et al., 2010, Katz et al., 2011). Systemic injection of NGF induced a long-lasting myalgia including jaw muscle pain (Petty et al., 1994). NGF injected into the masseter muscle of healthy subjects induced a local mechanical sensitization that lasted for 1–3 weeks as well as pain during yawning and chewing (Svensson et al., 2003, Svensson et al., 2008). These effects of NGF mimic some of the features of myofascial temporomandibular disorders (M-TMD), where patients suffer from a localized masseter muscle sensitivity upon palpation as well as pain during oral functions (Cairns, 2010). The magnitude of these symptoms was also greater in women than men (Svensson et al., 2003, Svensson et al., 2008). These results suggest that intramuscular NGF injections may be useful in modeling the tender points associated with M-TMD.
It is not clear how NGF injections induce prolonged mechanical sensitization of the masseter muscle. Injection of NGF into rat masseter muscle induced a TrkA receptor-mediated mechanical sensitization of nociceptors, which began within 30 min of injection and lasted for at least 3 h (Svensson et al., 2010). These findings suggest that a peripheral mechanism underlies the initiation of NGF-induced mechanical sensitization but do not shed light on its long duration. We speculate that the sensitizing effects of NGF might be due, in part, to an interaction between NGF and peripheral N-methyl-D-aspartate (NMDA) receptors on primary afferent nociceptors. Results from clinical and animal studies suggest that peripheral glutamate receptors might play a role in nociceptive signaling from musculoskeletal tissues in the orofacial region. NGF and glutamate are released during injury and inflammation and can be found in elevated levels in chronic pain conditions (Anand, 1995, Castrillon et al., 2010). Intramuscular injections of glutamate induced mechanical sensitization in the masseter muscle of humans and rats; however, the duration is only a few hours (Cairns et al., 2002, Cairns et al., 2003, Svensson et al., 2003). NGF-induced mechanical sensitization and glutamate-evoked discharge/pain both exhibited a sex-related difference with the greater response in females (Cairns et al., 2003, Svensson et al., 2003, Svensson et al., 2008). In rats, this difference appears to be due in part to an estrogen-mediated expression of NMDA receptor subtype 2B (NR2B) subunit containing NMDA receptors by masseter nociceptors in females (Woolley et al., 1997, Foy et al., 1999, Dong et al., 2007, McRoberts et al., 2007). Previous research has also found that the majority of peripheral NMDA receptors contain the NR2B subunit and that NMDA-evoked muscle afferent discharge can be attenuated by ifenprodil, a NR2B-selective NMDA antagonist, in both male and female rats (Li et al., 2004, Dong et al., 2007). In cultured neurons, NGF can induce release of glutamate through TrkA receptor activation (Numakawa et al., 2003, Raiteri et al., 2003) and can also increase NMDA receptor currents by phosphorylation and/or by increasing receptor expression (Bai and Kusiak, 1997, Jarvis et al., 1997, Di Luca et al., 2001). These results suggest that NGF could influence the excitability of masseter nociceptors by altering the activity of peripheral NR2B subunit containing NMDA receptors.
This study aimed to examine whether NGF induces a prolonged mechanical sensitization of rat masseter muscle by increasing NMDA receptor activity and if so, whether this sensitization exhibits a sex-related difference. The study further examined whether putative nociceptive fibers in the masseter muscle of healthy humans express NMDA receptors. Understanding the role of peripheral NMDA receptors in NGF-induced muscle pain may provide further insights into chronic muscle pain development.
Section snippets
Animals
Male (301–426 g, n = 98) and female (234–299 g, n = 95) Sprague–Dawley rats were used for all experiments. Animals were housed in groups of two with a 12-h light/dark cycle. Food and water were given ad libitum. All animal procedures were reviewed and approved by the University of British Columbia Animal Care Committee.
Administration of NGF and dl-2-amino-5-phosphonovaleric acid (APV)
Intramuscular injection of NGF (25 μg/ml, 10 μl, Sigma, St. Louis, MO, USA) and vehicle (phosphate-buffered saline (PBS), 10 μl, Sigma, St. Louis, MO, USA) was made into the masseter
Results
To determine that mechanical threshold was due to muscle stimulation and not response from the skin, 2.5% lidocaine/2.5% prilocaine cream (EMLA cream, AstraZeneca, Missisauga, ON, Canada) was applied topically on the shaved skin over the masseter muscle of three male rats to block mechanical sensation from the skin. The pinch test was performed on the skin with forceps to assess the analgesic effect of lidocaine. At 30 min post treatment, no response to the pinch test was observed. Mechanical
Discussion
NGF is an important peripheral pain mediator and may contribute to the development of chronic muscle pain (Bennett, 2001, Chao, 2003, Pezet and MacMahon, 2006). Intramuscular injections of NGF into the masseter muscle of healthy subjects induce a local mechanical sensitization that begins within hours of the injection and lasts for 1–3 weeks, and is more pronounced in women than in men (Svensson et al., 2003, Svensson et al., 2008). Injection of NGF into the rat masseter muscle induced a
Acknowledgements
Research was supported by funding from the Faculty of Phamaceutical Sciences, the University of British Columbia. BEC was supported by a Canada Research Chair. None of the authors report a conflict of interest.
References (50)
Nerve growth factor regulates nociception in human health and disease
Br J Anaesth
(1995)- et al.
Nerve growth factor up-regulates the N-methyl-D-aspartate receptor subunit 1 promoter in PC12 cells
J Biol Chem
(1997) - et al.
Systemic administration of monosodium glutamate elevates intramuscular glutamate levels and sensitizes rat masseter muscle afferent fibers
Pain
(2007) - et al.
Glutamate-induced sensitization of rat masseter muscle fibers
Neuroscience
(2002) - et al.
Sex-related differences in NMDA-evoked rat masseter muscle afferent discharges result from estrogen-mediated modulation of peripheral NMDA receptor activity
Neuroscience
(2007) - et al.
Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis
Pain
(2010) - et al.
Efficacy and safety of tanezumab in the treatment of chronic low back pain
Pain
(2011) - et al.
Central sensitization: a generator of pain hypersensitivity by central neural plasticity
J Pain
(2009) - et al.
Electrophysiological characterization of N-methyl-D-aspartate receptors in rat dorsal root ganglia neurons
Pain
(2004) - et al.
Spinal NMDA receptors and nociception-evoked release of primary afferent substance P
Neuroscience
(2008)
Cellular mechanisms of the acute increase of glutamate release induced by nerve growth factor in rat cerebral cortex
Neuropharmacology
Masticatory myalgias
Pain Forum
Glutamate-evoked pain and mechanical allodynia in the human masseter muscle
Pain
Human nerve growth factor sensitizes masseter muscle nociceptors in female rats
Pain
Nociceptors–noxious stimulus detectors
Neuron
Glutamate NMDAR1 receptors localised to nerves in human Achilles tendons. Implications for treatment?
Knee Surg Sports Traumatol Arthrosc
Chronic tendon pain: no signs of chemical inflammation but high concentrations of the neurotransmitter glutamate. Implications for treatment?
Curr Drug Targets
Role of presynaptic glutamate receptors in pain transmission at the spinal cord level
Curr Neuropharmacol
Human temporomandibular joint and myofascial pain biochemical profiles: a case-control study
J Oral Rehabil
Neurotrophic factors: important regulators of nociceptive pain
The Neuroscientist
Pathophysiology of TMD pain – basic mechanisms and their implications in pharmacotherapy
J Oral Rehabil
Ketamine attenuates glutamate-induced mechanical sensitization of the masseter muscle in human males
Exp Brain Res
Activation of peripheral NMDA receptors contributes to human pain and rat afferent discharges evoked by injection of glutamate into the masseter muscle
J Neurophysiol
Effect of a peripheral NMDA receptor antagonist on glutamate-evoked masseter muscle pain and mechanical sensitization in women
J Orofac Pain
Interstitial glutamate concentration is elevated in the masseter muscle of myofascial temporomandibular disorder patients
J Orofac Pain
Cited by (55)
Involvement of GABAergic, glutamatergic, opioidergic, and brain-derived neurotrophic factor systems in the trigeminal neuropathic pain process
2023, Neuroscience LettersCitation Excerpt :In addition, we suggest that the upregulation of GABA receptors is due to a decrease in endogenous GABA release. Wong and colleagues demonstrated that peripheral nerve injury induces selective apoptosis of GABAergic interneurons, resulting in a reduction in GABA inhibitory amino acid synthesis, with consequent loss of inhibitory tone in the transmission of nociceptive information [28]. Our hypothesis is supported by the lack of effect that diazepam, an indirect GABAA receptor agonist, had since its effect is dependent on endogenous GABA release.
Preclinical models of deep craniofacial nociception and temporomandibular disorder pain
2021, Japanese Dental Science ReviewCitation Excerpt :The greater prevalence of females in TMD patients cannot be ignored to discuss the basis for TMD pain [43,78,79]. Evidence has demonstrated the sex differences in the deep craniofacial nociception [37,80–82]. The underlying mechanisms of sex differences in TMD pain have been investigated in the preclinical studies from the point of changes in the level of sex hormones, and several hormones such as estrogen [83–85], progesterone [86,87] and testosterone [88] play roles.
Evaluation of Pain between Double Slot Orthodontic Brackets Versus Single Slot by Visual Analogue Scale and Saliva Biomarkers
2023, Journal of Medicinal and Chemical SciencesRole of Neurotrophins in Orofacial Pain Modulation: A Review of the Latest Discoveries
2023, International Journal of Molecular SciencesPreclinical orofacial pain assays and measures and chronic primary orofacial pain research: where we are and where we need to go
2023, Frontiers in Pain Research